About The Study: Although Canada is not the largest supplier of medications to the U.S., tariffs could raise costs and strain supply chains. This study estimates that $3 billion in U.S. pharmaceuticals depend on Canadian manufacturing, with 25% tariffs adding $750 million in cost. Although the Inflation Reduction Act provisions limit cost pass-through to some payers (i.e., Medicare), manufacturers may still adjust production or alter distribution, increasing supply chain fragility.
Corresponding Author: To contact the corresponding author, Mina Tadrous, PharmD, PhD, email mina.tadrous@utoronto.ca .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.4583)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.4583?guestAccessKey=6be4e13e-20fc-4326-ab0a-0fc3a41e27c0&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=033125
JAMA